I first wrote about a new, experimental chemotherapy drug, Torisel, in New Orleans at the 2009 ASH conference. Until I read this weekend’s article in The Myeloma Beacon, I hadn’t given Pfizer’s Torisel any thought.
Now Torisel is back in the news. See what you think:
Torisel And Velcade Combination Shows Promise As Treatment For Relapsed/Refractory Multiple Myeloma
By Melissa Cobleigh – Published: Jan 7, 2011 1:59 pm
According to the results of a Phase 1/2 clinical trial, Torisel in combination with Velcade was well tolerated and effective for the treatment of relapsed/refractory multiple myeloma.
Dr. Irene Ghobrial of the Dana-Farber Cancer Institute presented the results at the 2010 annual American Society of Hematology (ASH) conference held in Orlando last month.
Dr. Ghobrial said the trial results were promising in heavily pretreated myeloma patients and that the combination of Torisel (temsirolimus) and Velcade (bortezomib) warrants further evaluation.
Torisel is marketed by Pfizer and is currently approved for the treatment of advanced kidney cancer. It works by inhibiting a protein essential for cancer cell growth and division. A previous study showed that the overall response rate with Torisel alone is 43 percent in myeloma patients.
Go to: Torisel And Velcade Combination Shows Promise for more details.
What do I think? Torisel sounds like another secondary or combination “helper” drug, which helps primary novel therapy agents, like Velcade, work better.
Early test results look OK. No better than a half dozen others. But one positive I see is this: Since the drug is already FDA approved for use against kidney cancer, myeloma docs may be able to prescribe it “off label” to help stubborn, hard to treat multiple myeloma right away–and that’s good news!
Feel good and keep smiling! Pat